Akebia Therapeutics (NASDAQ: AKBA ) has filed a complaint in a district court against the U.S. Department of Medicare & Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS) challenging CMS's decision about a year ago to rescind Medicare Part D coverage of ...

CMS continues to deny Medicare beneficiaries with chronic kidney disease full access to this innovative therapy Akebia Therapeutics , Inc. (Nasdaq: AKBA), a fully integrated biopharmaceutical company focused on bettering the lives of people impacted by kidney disease, today filed a c...

Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will present at the 2019 Cantor...